BR112018001761A2 - uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética - Google Patents
uso de variantes de peptídeo natriurético tipo c para tratar a displasia esqueléticaInfo
- Publication number
- BR112018001761A2 BR112018001761A2 BR112018001761-2A BR112018001761A BR112018001761A2 BR 112018001761 A2 BR112018001761 A2 BR 112018001761A2 BR 112018001761 A BR112018001761 A BR 112018001761A BR 112018001761 A2 BR112018001761 A2 BR 112018001761A2
- Authority
- BR
- Brazil
- Prior art keywords
- skeletal dysplasia
- natriuretic peptide
- type
- peptide variants
- cnp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente revelação proporciona o uso de variantes de peptídeo natriurético tipo c (cnp) e novas composições e formulações farmacêuticas compreendendo peptídeos variantes de cnp para o tratamento de displasias esqueléticas, um ou mais sintomas de displasias esqueléticas, tais como crescimento ósseo longo ou velocidade de crescimento e outros distúrbios com um sintoma ou componente associado à displasia esquelética e/ou cnp.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562199081P | 2015-07-30 | 2015-07-30 | |
US62/199,081 | 2015-07-30 | ||
US201662320704P | 2016-04-11 | 2016-04-11 | |
US62/320,704 | 2016-04-11 | ||
PCT/US2016/044968 WO2017020034A1 (en) | 2015-07-30 | 2016-08-01 | Use of c-type natriuretic peptide variants to treat skeletal dysplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018001761A2 true BR112018001761A2 (pt) | 2018-09-18 |
Family
ID=56682280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018001761-2A BR112018001761A2 (pt) | 2015-07-30 | 2016-08-01 | uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética |
Country Status (19)
Country | Link |
---|---|
US (5) | US9907834B2 (pt) |
EP (1) | EP3328416B1 (pt) |
JP (3) | JP6882256B2 (pt) |
KR (1) | KR20180030414A (pt) |
CN (2) | CN108472336B (pt) |
AU (2) | AU2016298425B2 (pt) |
BR (1) | BR112018001761A2 (pt) |
CA (1) | CA2994280C (pt) |
CL (1) | CL2018000215A1 (pt) |
CO (1) | CO2018002328A2 (pt) |
DK (1) | DK3328416T3 (pt) |
FI (1) | FI3328416T3 (pt) |
HK (1) | HK1255864A1 (pt) |
IL (2) | IL257125B (pt) |
MX (2) | MX2018001314A (pt) |
PT (1) | PT3328416T (pt) |
RU (1) | RU2728567C2 (pt) |
TW (2) | TWI773649B (pt) |
WO (1) | WO2017020034A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9907834B2 (en) | 2015-07-30 | 2018-03-06 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
EP3574913A4 (en) * | 2017-01-24 | 2020-07-22 | Daiichi Sankyo Company, Limited | SMALL SIZE THERAPEUTIC AGENT |
KR102649069B1 (ko) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물 |
KR102058961B1 (ko) | 2018-07-28 | 2019-12-24 | 주식회사 엑소코바이오 | 엑소좀의 동결건조 방법 |
KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
JP7197310B2 (ja) * | 2018-08-31 | 2022-12-27 | 株式会社小松製作所 | 積込機械の制御装置および制御方法 |
WO2021030411A1 (en) * | 2019-08-12 | 2021-02-18 | Biomarin Pharmaceutical Inc. | Hydrophobic peptide salts for extended release compositions |
CN110514619B (zh) * | 2019-08-29 | 2021-01-29 | 山东科技大学 | 基于有偏估计的近红外定量分析模型构建方法 |
KR20220063220A (ko) * | 2019-09-16 | 2022-05-17 | 바이오마린 파머수티컬 인크. | Cnp 변이체 및 이의 접합체 |
TW202313663A (zh) | 2021-07-09 | 2023-04-01 | 美商拜奧馬林製藥公司 | C型利鈉肽變異體治療兒童骨骼發育不良 |
TW202334188A (zh) | 2021-12-07 | 2023-09-01 | 美商拜奧馬林製藥公司 | Cnp療法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0478797B1 (en) | 1990-04-20 | 1995-04-12 | Hisayuki Matsuo | Novel physiologically active peptide originating in hog |
JP3026354B2 (ja) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトcnp遺伝子及び前駆体蛋白 |
JP2809533B2 (ja) * | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Cnp類似体ペプチド |
AU6360394A (en) | 1993-03-03 | 1994-09-26 | Mayo Foundation For Medical Education And Research | Vasonatrin peptide and analogs thereof |
IL142118A0 (en) * | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
US7015195B2 (en) * | 2002-01-10 | 2006-03-21 | Osteotrophin, Llc | Treatment of bone disorders with skeletal anabolic drugs |
ES2465141T3 (es) | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
AR069409A1 (es) | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
WO2009086166A1 (en) * | 2007-12-19 | 2009-07-09 | Ekr Therapeutics, Inc. | Room temperature stable, lyophilized natriuretic peptide formulations |
HUE032582T2 (en) * | 2009-05-20 | 2017-09-28 | Biomarin Pharm Inc | Variants of C-type natriuretic peptide |
US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
US9266939B2 (en) * | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
WO2013058833A1 (en) * | 2011-10-19 | 2013-04-25 | Enobia Canada Limited Partnership | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
US9907834B2 (en) | 2015-07-30 | 2018-03-06 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
-
2016
- 2016-08-01 US US15/225,355 patent/US9907834B2/en active Active
- 2016-08-01 TW TW105124351A patent/TWI773649B/zh active
- 2016-08-01 TW TW111126119A patent/TWI820795B/zh active
- 2016-08-01 DK DK16750584.1T patent/DK3328416T3/da active
- 2016-08-01 WO PCT/US2016/044968 patent/WO2017020034A1/en active Application Filing
- 2016-08-01 BR BR112018001761-2A patent/BR112018001761A2/pt active Search and Examination
- 2016-08-01 JP JP2018504160A patent/JP6882256B2/ja active Active
- 2016-08-01 CN CN201680058019.9A patent/CN108472336B/zh active Active
- 2016-08-01 EP EP16750584.1A patent/EP3328416B1/en active Active
- 2016-08-01 CA CA2994280A patent/CA2994280C/en active Active
- 2016-08-01 CN CN202210522331.6A patent/CN114796460A/zh active Pending
- 2016-08-01 PT PT167505841T patent/PT3328416T/pt unknown
- 2016-08-01 RU RU2018106890A patent/RU2728567C2/ru active
- 2016-08-01 AU AU2016298425A patent/AU2016298425B2/en active Active
- 2016-08-01 FI FIEP16750584.1T patent/FI3328416T3/fi active
- 2016-08-01 MX MX2018001314A patent/MX2018001314A/es unknown
- 2016-08-01 KR KR1020187005634A patent/KR20180030414A/ko not_active Application Discontinuation
-
2018
- 2018-01-24 IL IL257125A patent/IL257125B/en active IP Right Grant
- 2018-01-25 CL CL2018000215A patent/CL2018000215A1/es unknown
- 2018-01-25 US US15/880,002 patent/US10646550B2/en active Active
- 2018-01-30 MX MX2023002973A patent/MX2023002973A/es unknown
- 2018-02-28 CO CONC2018/0002328A patent/CO2018002328A2/es unknown
- 2018-11-22 HK HK18114940.2A patent/HK1255864A1/zh unknown
-
2020
- 2020-04-01 US US16/837,910 patent/US11590204B2/en active Active
- 2020-04-01 US US16/837,905 patent/US11911446B2/en active Active
- 2020-11-04 IL IL278488A patent/IL278488B2/en unknown
-
2021
- 2021-05-06 JP JP2021078353A patent/JP7336482B2/ja active Active
-
2023
- 2023-01-20 US US18/157,573 patent/US20230293637A1/en active Pending
- 2023-02-08 AU AU2023200669A patent/AU2023200669A1/en active Pending
- 2023-08-21 JP JP2023133915A patent/JP2023144124A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018001761A2 (pt) | uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética | |
SV2018005614A (es) | Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias | |
DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
NI201600164A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
CL2020000422A1 (es) | Composiciones de glp-1 y sus usos. | |
BR112016024494A8 (pt) | análogo de peptídeo e seu uso | |
MX2019000047A (es) | Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras. | |
BR112018076215A2 (pt) | partículas e composições de nicotina | |
MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
DOP2020000082A (es) | Administración oral de análogos del péptido glp-1 | |
MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
AU2019363725B2 (en) | Stable semaglutide compositions and uses thereof | |
SV2017005585A (es) | Peptidos lipidados resistentes a proteasas | |
MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
MX2018004217A (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo. | |
BR112018070929A2 (pt) | peptídeos bioativos peguilados e seu uso | |
MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
BR112016024841A2 (pt) | composições estáveis de peptídeos neuroativos | |
AR105563A1 (es) | Uso de variantes del péptido natriurético tipo c para tratar displasia esquelética | |
BR112016020135A8 (pt) | mistura de composto, seus usos, composição farmacêutica, e conjunto (kit) | |
MX2018000418A (es) | Derivados de amida que tienen actividad multimodal contra el dolor. | |
UY35730A (es) | Composiciones farmacéuticas comprendiendo kisspeptin o sus derivados | |
BR112017002641A2 (pt) | compostos bicíclicos substituídos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |